Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763440 | 1.00 | MAPT (0.33) | MAPTPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL4766009 | 0.91 | TACR1 (0.33) | ALDH1A1ADORA2AADORA2BADORA1 | |
| SCHEMBL4766003 | 0.91 | TACR1 (0.33) | ALDH1A1ADORA2AADORA2BADORA1 | |
| SCHEMBL4765715 | 0.89 | MAPT (0.36) | MAPTALDH1A1PKML3MBTL1ADORA2A | |
| SCHEMBL4765703 | 0.89 | MAPT (0.36) | MAPTALDH1A1PKML3MBTL1ADORA2A | |
| SCHEMBL4769541 | 0.88 | MAPT (0.37) | MAPTPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL4769532 | 0.88 | MAPT (0.37) | MAPTPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL4867808 | 0.86 | ADORA2B (0.39) | MAPTPDE1APDE1BPDE1CALDH1A1 | |
| SCHEMBL4771502 | 0.85 | MAPT (0.35) | MAPTALDH1A1 | |
| SCHEMBL4771511 | 0.85 | MAPT (0.35) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |